AI assistant
TherapeuticsMD, Inc. — Director's Dealing 2022
Dec 10, 2022
35134_dirs_2022-12-09_4a8d13f1-1443-4198-a945-0a6de081717e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2022-12-06
Reporting Person: Donegan Michael C (Interim CFO/CAO/VP of Finance)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-06 | Common Stock | M | 2300 | $0.00 | Acquired | 4288 | Direct |
| 2022-12-06 | Common Stock | M | 380 | $0.00 | Acquired | 4668 | Direct |
| 2022-12-06 | Common Stock | M | 534 | $0.00 | Acquired | 5202 | Direct |
| 2022-12-06 | Common Stock | M | 262 | $0.00 | Acquired | 5464 | Direct |
| 2022-12-06 | Common Stock | S | 910 | $4.775 | Disposed | 4554 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-06 | Restricted Stock Units | $0.00 | M | 2300 | Disposed | Common Stock (2300) | Direct | |
| 2022-12-06 | Restricted Stock Units | $0.00 | M | 380 | Disposed | Common Stock (380) | Direct | |
| 2022-12-06 | Restricted Stock Units | $0.00 | M | 534 | Disposed | Common Stock (534) | Direct | |
| 2022-12-06 | Restricted Stock Units | $0.00 | M | 262 | Disposed | Common Stock (262) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,476 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.76 and $5.29, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F4: The RSUs vested in two equal installments on November 24, 2021 and November 24, 2022.
F5: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.
F6: The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.
F7: Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.